# Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

> **NCT02108002** · PHASE1 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 7 (actual)

## Conditions studied

- Von Hippel-Lindau Disease

## Interventions

- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT02108002
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-05
- **Primary completion:** 2018-09-12
- **Final completion:** 2018-09-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02108002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02108002, "Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02108002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*